harmacy has greatly evolved since the initial Medicare statutes were enacted in 1965, but pharmacists have not received federal recognition as health care providers. In some states, however, Medicaid and pharmacy practice acts have been revised to include pharmacists among recognized health care providers. In other states, Medicaid administrators will not authorize reimbursement of cognitive services by pharmacists until they achieve Medicare provider recognition status. Moreover, most third-party payers do not have formal policies preventing or allowing reimbursement to pharmacists for clinical pharmacy services, with many referencing restrictive federal or state policies. Despite these barriers, new opportunities for cognitive service reimbursement may be forthcoming.
Federal legislation
Great strides have been made to educate the U.S. Congress about the benefits of the patient care services provided by pharmacists. The American Society of Health-System PharPurpose. The legislative and regulatory issues surrounding the reimbursement of pharmacists for cognitive services are reviewed and billing practices for a pharmacist-physician collaborative drug therapy management service (DTMS) in a family medicine clinic are examined. A case study is offered to illustrate the real-world application of these practices. Summary. As regimens of prescription medications have become more complex and the potential for adverse drug reactions and interactions has increased, the need for individualized optimal drug therapy and drug-therapy experts has grown. Pharmacists, who are professionally trained to be an integral part of the medical team, are well prepared to ensure optimal drug therapy and medication safety for patients. Consequently, collaboration between physicians and pharmacists can lead to improved patient care and reduced medication errors. The following 10 steps are recommended for establishing a successful collaborative DTMS: (1) establish a working relationship with physician colleagues, (2) assess the needs of your patients, (3) draft collaborative DTMS protocols and agreements, (4) apply for credentialing status within your health organization, (5) consult the billing office staff at the clinic, (6) design a clinic-encounter form, (7) identify and train support personnel, (8) allocate resources, (9) advertise the DTMS, and (10) evaluate and improve your service. Conclusion. Establishing a DTMS presents many challenges and obstacles, but they should not lead to discouragement. Rather, pharmacists should be diligent and continue to explore ways in which they could provide optimal medication therapy to patients through appropriate channels that also facilitate reimbursement.
Index terms: Certification; Errors, medication; Patient care; Pharmaceutical services; Pharmacists; Physicians; Professional relations; Professionalism; Regulations; Reimbursement; Toxicity Am J Health-Syst Pharm. 2004; 61: macists (ASHP) has made the granting of Medicare provider status to pharmacists its top legislative priority, and all of the major national pharmacy organizations are supporting the increased use of pharmacists as medication-use experts and advocating for proper payment for these services for all Medicare prescriptiondrug beneficiaries. Two pieces of legislation that will affect the provider status of pharmacists have been intro-duced in recent years. During the 107th Congress, the Medicare Pharmacist Services Coverage Act and the Medicare Medication Therapy Management Services Coverage Act were introduced in 2001 and 2002, respectively. Because the intent of these two pieces of legislation is similar, ASHP has worked to educate the 108th Congress about the important distinctions between them and toward advancing a unified approach to making pharmacists' medicationtherapy management services accessible to Medicare beneficiaries.
The cause of provider status for pharmacists has been furthered in other ways. In a June 2002 report to Congress, the Medicare Payment Advisory Commission (MedPAC) acknowledged the value of drug therapy management services (DTMSs) provided by pharmacists and recommended that the Department of Health and Human Services (HHS) assess contemporary models of DTMS to determine how they can be incorporated into Medicare. 1 In July 2002, the Department of Labor HHS appropriations bill included language directing the Secretary of HHS to act on MedPAC's recommendation; however, Congress did not finish work on this legislation, and it was not signed into law. 2 National pharmacy organizations are now working with the Secretary of HHS to evaluate health care delivery models to ensure that Medicare beneficiaries receive these pharmacist-provided services.
The impact of this federal legislation is not inconsequential, as thirdparty and other payers usually follow the lead of Medicare in setting their reimbursement policies. An alternative option to seeking a Medicaid waiver through CMS is to pursue legislation to amend the state Medicaid plan. In 1996, Wisconsin began the nation's first online payment system to financially reward pharmacists for finding and solving medication problems and to encourage collaboration among health care providers to improve medication therapy outcomes. The Wisconsin Medicaid Pharmaceutical Care Payment System pays pharmacy providers an enhanced dispensing fee for 28 unique DTMSs, ranging from patient education to the dispensing of the most appropriate drug. 4 Enhanced dispensing fees range from $9.45 to $40.11 when the service provided is deemed payable and results in a positive outcome. Payment levels are based on time and intensity of service, and actual service dispensing fees (exclusive of traditional product dispensing fees) average $60-$75 per hour. Pharmacists code the reason for the medication management service, the action taken, the result of the action, and the level of service provided (designated time segments). To make Wisconsin Medicaid even more flexible, plans that would permit payment to pharmacists for medication management service fees separate from dispensing fees would expand the availability of reimbursable disease management services. This would enable pharmacists and physicians to address high-risk patients using complex medication regimens and is under consideration.
Although Wisconsin Medicaid has not yet conducted a comprehensive cost-benefit study of the program, the success of the program has attracted the private payer community, as several health plans have joined Medicaid in paying pharmacists for event-based and disease management services. In September 2002, Wisconsin's "Senior Care" program became the first program in the country to provide drug and service coverage for qualified seniors through the use of state (>$50 million) and federal (>$500 million) funding. This program allows qualified seniors to receive medication and pharmacist cognitive services with 5-to 15-minute appointments for pharmacist-directed interventions. Although Wisconsin is similar to other states in experiencing pressures from budget deficits to reduce reimbursement for pharmacist dispensing fees, the reimbursement of successful cognitive service interventions should not be affected.
The 6 The program began with pharmacists contracting with the city of Asheville, North Carolina, to provide diabetes management for city employees. Total health care costs decreased by $2000 per enrollee per year, and all quality-of-life and ability-tofunction parameters significantly improved. Because of the program's success, pharmacist services were expanded to the management of asthma, hypertension, and hyperlipidemia. In addition to city employees, the program was offered to employers in the area and has triggered the start of similar employer programs in other areas of the state.
Federal developments
Two major federal developments occurred in 2003 that could dramatically affect the reimbursement landscape for pharmacists. The Medicare Prescription Drug Bill of 2003 was passed by both the House of Representatives and Senate and is currently undergoing final review of program details. 7 A key component of this bill requires Medicare sponsors to cover pharmacist-provided DTMS. Patients taking multiple medications or suffering from selected chronic diseases (asthma, diabetes, hypertension, hyperlipidemia, and congestive heart failure) would be eligible to receive these services.
The second federal bill of importance in 2003 was the reintroduction of the Medicare provider status legislation, entitled the Medication Therapy Management Act of 2003. 8 This bill purposely uses the same language as the Medicare prescriptiondrug bill in defining pharmacist services as DTMS. While the Medicare prescription-drug bill may produce inconsistent reimbursement across state third-party provider plans, the "provider bill" payment mechanisms will be set by CMS, and pharmacist DTMS will be defined by each state's practice act or regulatory authority. The impact of the "provider bill," therefore, would be broader for most pharmacists and not be affected by a private payer's potential narrow scope of coverage.
Developing a collaborative DTMS
As discussed above, legislative and regulatory factors at the federal and state levels may influence the reimbursement of pharmacists' cognitive services. A key to reimbursement success is for pharmacists to educate legislators about the value of their services and offer themselves as a resource to legislators on pharmacy issues. Many pharmacists, however, are not actively engaged in collaborative DTMSs, even in the states that have legislative approval, because of various obstacles including (1) difficulty obtaining physician acceptance, (2) lack of support from directors and support personnel, (3) slow processes for getting credentialing status, (4) inadequate knowledge of billing and clinical skills, (5) indifferent attitude of pharmacy practitioners, (6) lack of a cohesive vision for practice models, (7) insufficient space to perform the services, and (8) outcomes failing to meet expectations. We offer SPECIAL FEATURE Collaborative drug therapy management advice about establishing a collaborative DTMS.
We began a pharmacist-physician collaborative DTMS in a family medicine clinic in 2000; the collaborative service protocols were approved and eventually used by all 10 physicians in our clinic. Based on our experience, we recommend that pharmacists take the following 10 steps to establish such a service and receive reimbursement.
Step 1: Establish a working relationship with physician colleagues. Providing pharmaceutical care services that are eligible for reimbursement requires pharmacists to have the ability to build dedicated relationships with patients and other health care providers. A collaborative DTMS, as described in many state legislatures, is a collaborative practice between pharmacists and physicians in the care of patients who have established relationships with the physicians. It is imperative, therefore, that pharmacists establish and maintain a good working relationship with physician colleagues who will refer their patients for pharmaceutical care. Physicians may have different expectations for pharmacists, 9 but several pharmacy and medical organizations have endorsed cognitive services provided by pharmacists. ASHP supports participation of pharmacists in collaborative DTMSs. 10 The standards of practice as approved by the American College of Clinical Pharmacy for clinical pharmacists include developing professional relationships through effective communication. 11 The American Pharmacists Association has established an Advanced Practice Institute to train pharmacists to engage in collaborative practices. 12 Primary care physician groups, such as the American Academy of Family Physicians and the American College of Physicians-American Society of Internal Medicine, support pharmacistphysician collaborative practice to improve patient safety and reduce medical errors. 13 Pharmacists can enhance their working relationships with physician colleagues by being resourceful and willing to help. When called upon for a drug information consultation, pharmacists can provide information beyond what is asked or expected by anticipating parameters needed to achieve optimal drug therapy. One way of doing this is to provide updated evidence-based drug information pertinent to each patient's needs.
Step 2: Assess the needs of your patients. The patient population of each ambulatory care clinic is unique and requires pharmacists to know the needs of individual patients, as well as the characteristics of the entire population. Such knowledge can be gained using several approaches. Generally, a pharmacist can help rule out drug-related reactions, interactions, or adverse effects for an individual patient by reviewing his or her medication regimen. With this approach, the pharmacist maintains a more traditional role. By adopting a disease management approach, the pharmacist can identify patients who should receive pharmaceutical care services and drug therapy counseling on the basis of diseases commonly found in primary care patients, such as diabetes, hypertension, hypercholesterolemia, osteoporosis, arthritis, and asthma. Healthy People 2010 initiatives also identified medical conditions that could be comanaged by pharmacists.
14 By focusing on the medications taken by patients that require frequent monitoring or dosage adjustments, pharmacists can offer drug-therapy management for patients taking medications such as anticoagulant or hormone replacement drugs.
Step 3: Draft collaborative DTMS protocols and agreements. Before a collaborative DTMS can be implemented, business agreements and clinical protocols must be drafted and copies of those documents made readily retrievable. Depending on state board of pharmacy requirements, a collaborative practice agreement usually contains a brief description of the types of services to be offered, the names and license numbers of participating pharmacists and physicians, and the address of the clinic where the services will be rendered to patients. The incident-to billing allowances set by CMS require the pharmacist who provides DTMSs to be a full-time, part-time, or leased employee of the physician or the physician's institution.
Once the pharmacist and physician identify the specific diseases or drug therapies to be comanaged, collaborative practice protocols should be written and compiled. Each protocol may contain evidence-based clinical guidelines, services to be performed by pharmacists (e.g., medication counseling, disease management, specifying laboratory tests and physical examinations to be performed), as well as any limitations agreed upon by both the pharmacist and physician. Evidence-based clinical guidelines are excellent references for collaborative practice protocols. Many clinical guidelines can be retrieved from Web sites, such as the National Guideline Clearinghouse (www.guideline.gov) and the National Heart, Lung, and Blood Institute's listing of clinical practice guidelines (www.nhlbi.nih.gov/guidelines/). We have developed collaborative service protocols for general approach (e.g., assessment of medication therapy, adverse effects, complications, interactions), asthma, diabetes, hyperlipidemia, hypertension, arthritis, thyroid disease, osteoporosis, anticoagulation, and hormone replacement therapy.
Such collaborative DTMS protocols enable the pharmacist to (1) collect and review medication histories through patient interviews, (2) perform routine drug-therapy-related physical assessment procedures, (3) order medication-related monitoring tests and evaluate the results with the approval of the physician, (4) ad-SPECIAL FEATURE Transitions Collaborative drug therapy management just dosage and dose intervals to improve medication efficacy and safety, (5) recommend the initiation or discontinuation of drug therapy when appropriate and agreed upon by the physician, and (6) perform any other drug-therapy-related act delegated by the physician.
Step 4: Apply for credentialing status within your health organization. Even though pharmacists in many states cannot obtain provider status under current laws, they still need to be credentialed by their institution because each organization has its own procedural requirements and paperwork that allow pharmacists to be involved in a collaborative practice, have chart documentation privileges, and obtain liability insurance coverage. Institutional credentialing requires pharmacists to have proof of pharmacist licensure, professional continuing-education credits, certificates in disease or drug management for some diseases (e.g., diabetes management, anticoagulation management), and letters of recommendation. Applying for institutional credentialing can be a protracted process and requires patience.
Step 5: Consult the billing office staff at the clinic. Pharmacists must be willing to make an initial effort to educate themselves about billing services to successfully obtain appropriate reimbursement amounts with appropriate billing rates. The physician group with whom a pharmacist collaborates will most likely have wellestablished billing policies and procedures, and its billing specialists can offer guidance in preparing a bill for services rendered. These billing specialists can review the pharmacist's patient-specific SOAP (subjective, objective, assessment, and plan) notes and billing records and make helpful suggestions. In addition, some published articles may serve as helpful references. [15] [16] [17] [18] [19] In our clinic, we decided that the clinical pharmacist would collaboratively manage patients who had established relationships with their family physicians and required complex care. We determined that the Current Procedural Terminology (CPT) billing codes most commonly used for such collaborative management are 99213, 99214, and 99215. We also determined that the counseling codes (e.g., V65.49) or the ancillary service codes (e.g., the finger-stick glucose blood monitoring code 82962) could be applied if appropriate.
Step 6: Design a clinic-encounter form. Whether the pharmacist decides to use the format of a SOAP note or a pharmacotherapy consult note, he or she should design a clinicencounter form so that patient visits will be properly and efficiently documented. These forms can be disease specific (e.g., for a diabetes visit) or medication specific (e.g., for an anticoagulation therapy visit). Elements to be included in the clinic encounter form are based on the collaborative service protocols and should also include the seven components necessary for billing: medical history, physician examination, medical decision-making, counseling, coordination of care, nature of the presenting problem, and time spent with the patient. If your clinic uses an electronic medical record system, these templates can be designed and incorporated to help you accurately and efficiently document the pharmaceutical care service provided to patients.
Step 7: Identify and train support personnel. In a group practice, teamwork among support personnel is key to the success of a pharmacistphysician collaborative practice. These support personnel may include a scheduler, to make appointments for patients; a receptionist, to give patients the correct forms to fill out; a nurse, to prepare an examination room, take the patients' vital signs, and coordinate the encounter for both the pharmacist and the physician; a billing clerk, to check and bill the CPT codes corresponding to the services provided; and an administrator, to evaluate billing and reimbursement outcomes. In our clinic, we created an appointment template to link patient visits with both the physician and the pharmacist, allowing the patient to have a 45-minute visit with the pharmacist before a 15-minute visit with the physician.
Step 8: Allocate resources. A successful business plan for a collaborative DTMS also requires the proper allocation of resources and identification of budgetary needs. Such resources include sufficient space, adequately equipped examination rooms, reference books and computer software containing up-to-date drug information, medical instruments to perform physical examinations, and patient-care-monitoring tools, such as glucometers and glucometer-compatible computer software programs. Overhead costs must also be considered.
Step 9: Advertise the DTMS. Medical directors and clinic managers have experience advertising medical services and can help develop creative and effective ways to market the pharmacist-physician collaborative practice. DTMSs can be marketed through inservice education programs for physician staff and support personnel, flyers, patient letters or post cards, dedicated Web sites, and appointment reminders sent to patients. In our case, inservice programs for both physicians and clinic staff (nurses, medical assistants, schedulers) were offered after the medical director, clinic manager, and pharmacist had designed the collaborative service model to be implemented in the clinic. Post cards that contained information about the pharmacist were printed and placed at the clinic's reception desk. We also printed referral slips to schedule appointments for physician colleagues to use and give to patients as reminders. For collaborative services between physician and pharmacist to be effective, the pharmacist must be SPECIAL FEATURE Collaborative drug therapy management available and visible to the physician and clinic staff. The pharmacist can simply be present at the clinic to help answer any drug information questions, to interview patients for a
Step 10: Evaluate and improve your service. Data regarding clinical outcomes, billing, and reimbursement are helpful in evaluating pharmacist-physician collaborative practices. Clinical outcomes studies can evaluate disease-specific indicators, such as the level of fasting blood glucose or glycosylated hemoglobin. [20] [21] [22] [23] [24] [25] [26] Billing and reimbursement data can be further stratified by referring physician, disease, and insurance type. In order to generate a report comparing billing and reimbursement data for collaborative services, the clinic needs to maintain a record of patients seen and the dates of the visits during which the services were provided. Clinic administrators can then retrospectively query reimbursement data, including the CPT codes used, the patient's copayment, the amount the clinic billed for the services provided, and the actual reimbursement amounts the clinic received from the insurance carriers. A patient satisfaction survey is also a helpful way to collect suggestions for improving the collaborative practice.
Experience in a collaborative DTMS
When we designed our collaborativeservice practice, our purpose was to improve the quality of patient care by (1) optimizing medication regimens for patients, (2) educating patients about medications and diseases, and (3) decreasing disease-and medication-related complications in patients. During the initial stages, we faced many administrative hurdles as we worked to establish our collaborative service. We have overcome these challenges and have witnessed clinical improvements in our patients.
It has been a rewarding experience for the clinical pharmacist to work with a group of family medicine physicians. Through a collaborative DTMS, the pharmacist also has the opportunity to work with physicians on designing therapeutic protocols to be implemented in the clinic, evaluating disease management outcomes and drug utilization, and conducting clinical research studies.
Family physicians are well poised to collaborate with clinical pharmacists. Primary care physicians, as part of their training, are imbued with the belief that teamwork is critical to the optimal delivery of health care. It is impossible for a generalist to "know everything." Other team members can offer alternative suggestions for both diagnosis and therapy. This is especially true in our experience with doctor of pharmacy faculty members in both inpatient and outpatient settings.
The patient population in many family medicine clinics tends to be older, have the "big three" chronic diseases (i.e., diabetes, hyperlipidemia, and hypertension), and be treated with multiple medications. The clinical pharmacist has consulted with the physicians regarding patients whose chronic diseases have been especially difficult to control. Such expertise may also be used to review patient charts for potential medication interactions. This is especially important in training clinics, where medical residents and students are learning the proper use of many medications in providing care to their patients.
Experience has demonstrated how clinical pharmacists can provide upto-date information to physicians on the latest treatment recommendations for the many diseases they frequently manage. With their interpersonal skills and clinical training, pharmacists can also be a resource for patients. The clinical pharmacist has consulted with patients who have poorly controlled diabetes or hyperlipidemia, take multiple drugs, and have unusual drug reactions or interactions. We plan to expand this program to include formal diabetes education in group sessions and open an anticoagulation clinic.
The expertise of a pharmacist is important to any clinical practice that desires to measure and improve clinical outcomes. In our clinic, the pharmacist has played an active role in clinical research by encouraging the physicians to look for ways to reduce medication errors and suggesting innovative primary care outcome studies that involve medication use. From a service point of view, clinicians and patients alike have appreciated the availability of a pharmacist in our clinic. We have also found that this can be a financially successful endeavor.
Documentation
The clinic encounter note used by any clinician must be designed for the direct documentation of the patient care provided, appropriate billing, adherence to legal requirements, and continuity of care. The note should contain the reason (the chief complaint) for the patient's visit and a statement of medical necessity, the source of referral or the name of the collaborating physician, a description of the services provided to the patient, the level of intensity of the evaluation and services, and the total time spent with the patient.
There are many types of notes pharmacists can use to document the services they provide, including the SOAP note, pharmacotherapeutic workup reports, and pharmacotherapy consultation notes. The following section will describe the SOAP note format for billing for collaborative services provided to established patients who are referred to the phar-SPECIAL FEATURE Transitions Collaborative drug therapy management macist by physicians. The methods described are based on CMS guidelines for coding and documenting clinic encounters for appropriate billing. 27 As mentioned earlier, it is important that pharmacists work with billing experts in their organization to be credentialed and trained to comply with organizational regulations.
The SOAP note describes the evaluation conducted and the management decisions made during clinical encounters with patients. SOAP notes contain three key components-history, examination, and medical decision-making-and four contributory componentspatient counseling, coordination of care, problem severity, and time spent with the patient-that are used to determine the CPT codes and the appropriate billing level for each patient's clinic encounter. Both the pharmacist and physician should date and sign the SOAP note.
History. The history includes a chief complaint, a history of the present illness, a review of systems, and past, family, and social histories. The chief complaint is a required element on the chart document. The history of the present illness assesses the location, quality, severity, duration, timing, context, modifying factors, and associated signs and symptoms of a particular medical condition or disease. The review of systems is usually organized by organ systems (i.e., constitutional symptoms; eyes; ear, nose, throat; cardiovascular; respiratory; gastrointestinal; genitourinary; musculoskeletal; integumentary; neurologic; psychiatric; endocrine; hematologic and lymphatic; and allergic and immunologic systems). The past, family, and social histories include the patient's own past medical history (e.g., prior major illnesses and injuries, hospitalizations, operations, medications, allergies, immunization records, dietary status), family medical history, and social history (i.e., employment; use of recreational drugs, alcohol, and tobacco; level of education; sexual history). The history is classified as problem focused if it contains the chief complaint and a brief history of the present illness (1-3 items); expanded problem focused if it contains the chief complaint, brief history of the present illness (1-3 items) , and problem-pertinent review of systems (1 organ system); detailed if it contains the chief complaint, extended history of the present illness (≥4 items), extended review of systems (2-9 organ systems), and pertinent past, family, and social histories (at least 1 of the 3 past, family, and social history items); or comprehensive if it contains the chief complaint, extended history of the present illness (≥4 items), complete review of systems (≥10 organ systems), and complete past, family, and social histories (at least 2 of the 3 past, family, and social history items).
Examination. The examination component can be evaluated on the basis of either multisystem or singlesystem nomenclature. A multisystem examination includes assessment of constitutional signs; the eyes; the ears, nose, and throat; the neck; and the respiratory, cardiovascular, chest (breast), gastrointestinal, genitourinary, lymphatic, musculoskeletal, dermatological, neurologic, and psychiatric systems (Table 1 provides examples of elements of a multisystem physical examination). A singlesystem examination includes assessment of the eyes; ears, nose, and throat; and respiratory, cardiovascular, genitourinary, hematologic, lymphatic, immunologic, musculoskeletal, dermatological, neurologic, or psychiatric system. The examination is classified as problem focused if it is limited to physical assessment of the affected area or system, including 1-5 elements in at least 1 organ in a multisystem examination or 1-5 elements in a single-system examination; expanded problem focused if it is limited to physical assessment of the affected area or system and other symptom-related systems, including either over 6 elements in at least 1 organ in a multisystem examination or over 6 elements in a single-system examination; detailed if it is an extended physical assessment of the affected area or system and other systems, including either 2 elements in at least 6 organs or 12 elements in at least 2 systems in a multisystem examination or over 12 elements in a single-system examination (with the exception of eye and psychiatric systems that only require over 9 elements in a single-system examination); or comprehensive if it is either a general multisystem physical assessment (all elements in at least 9 organs) or a complete physical assessment (all elements) of a single system.
Medical decision-making. Medical decision-making refers to the complexity of the clinic encounter in establishing a diagnosis or selecting a management option. The number of medical problems, the amount or complexity of the medical data to be reviewed, and the risk of complications influence medical decisionmaking.
The number of medical problems each patient has are scored as follows: a self-limiting or minor problem (1 point), an established problem that is stable or improving (1 point), an established problem that is worsening (2 points), a new problem without additional workup planned (3 points), and a new problem with additional workup planned (4 points). The total score is calculated by multiplying the number of problems and the sum of points; however, the maximum total for a self-limiting or a minor problem is 2 and that for a new problem without additional workup planned is 3. The total scores are also stratified according to the complexity of the data they represent: minimal (1 point), limited (2 points), multiple (3 points), and extensive (4 points) levels of complexity.
The quantity or complexity of the data to be reviewed is also scored: SPECIAL FEATURE Collaborative drug therapy management review or order clinical tests (1 point), review or order tests with CPT radiology codes (1 point), review or order tests with CPT medicine codes (1 point), discuss test results with the performing physician (1 point), review past records or take history from patient's family, caretaker, or other source (2 points), and independently review an image, tracing, or specimen (2 points). The totals of these scores are also stratified: minimal (0-1 point), limited (2 points), moderate (3 points), and extensive (4 points) levels of complexity.
The risk of complications is determined for the presenting problem (category 1), the diagnostic procedure ordered (category 2), and the management option selected (category 3). There are four levels of risk (i.e., minimal, low, moderate, and high). Category 1. For the presenting problem, a self-limiting or minor problem (e.g., a cold) has a minimal level of risk; two or more selflimiting or minor problems, one stable chronic illness, or an acute uncomplicated illness has a low level of risk; two or more stable chronic illnesses, one or more chronic illnesses with progression, mild exacerbation, adverse effects of treatment, or an acute complicated illness has a moderate level of risk; and one or more chronic illnesses with progression, severe exacerbation, adverse effects of treatment, life-threatening acute or chronic illnesses, or an abrupt change in neurologic status (e.g., seizure, transient ischemic attack) has a high level of risk.
Category 2. For the diagnostic procedure, laboratory tests requiring venipuncture, urinalysis, or electrocardiogram have a minimal level of risk; clinical laboratory tests requiring arterial puncture or skin biopsies have a low level of risk; a cardiac stress test has a moderate level of risk; and cardiovascular imaging with contrast media and risk factors has a high level of risk.
Category 3. For the management option, applying bandages, changing an injury wound dressing, or recommending rest at home has a minimal level of risk; recommending overthe-counter drugs, minor surgery, physical therapy, or occupational therapy has a low level of risk; prescribing medications has a moderate level of risk; and prescribing drug therapy that requires intensive monitoring for toxicity or administering parenteral medications has a high level of risk.
Levels of decision-making. The levels of medical decision-making are determined by the guidelines listed below. Note that at least two of the three elements must be met or exceeded to qualify any particular level of medical decision-making. Decision-making is classified as straightforward if the number of medical problems, the amount or complexity of data to be reviewed, and the risk of complications are all minimal; low complexity if the number of medical problems is limited, the amount or complexity of the data to be reviewed is limited, and the risk of complications is low; moderate complexity if the patient has multiple medical problems, the amount or complexity of data to be reviewed is moderate, and the risk of complications is moderate; or high complexity if the patient's medical problems are extensive, the amount or complexity of the data to be reviewed is extensive, and the risk of complications is high.
Counseling. Counseling provided to patients or family members on the risk and benefit of treatment options needs to be documented, as well as giving instructions regarding treat- 
Examples of Physical Examination Elements in a Multisystem Nomenclature

Elements of Examination Organ or System
Vital signs: blood pressure, pulse rate, respiration rate, temperature, height, weight; general appearance Inspection, examination of irises and pupils, visual acuity, ophthalmoscopic examination Inspection of ears and nose; otoscopic examination; hearing evaluation, inspection of nasal cavity; inspection of buccal mucosa, teeth, and gums; examination of oral cavity Inspection, palpation, percussion, auscultation Palpation, auscultation, carotid arteries, pedal pulses Inspection or palpation of muscles in at least one of the following areas: (1) head and neck, (2) ment and/or follow-up plans. Education provided to patients about the importance of medication compliance and risk-factor reduction also needs to be documented. If more than 50% of time is spent counseling the patient during the visit, this should be noted in the patient's chart as well. Time is considered the key factor for qualifying a specific level of billing and coding (e.g., CPT code of V65.49).
Coordination of care. Coordinating care for the patient's disease management includes making proper referrals (e.g., to ophthalmologists, podiatrists, cardiologists, radiologists, oncologists). Efforts in coordinating care during the office visit must be documented.
Problem severity. The severity of patients' presenting problems can be stratified into five levels: minimal if the problem does not require that a physician be present, though the physician will supervise treatment; self-limited or minor if the problem is transient and has a good prognosis; low severity if the problem has a low risk of morbidity and mortality without treatment; moderate severity if the problem has a moderate risk of morbidity and mortality without treatment; and high severity if the problem has a high risk of morbidity and mortality without treatment.
Time spent with the patient. The actual face-to-face encounter with the patient must be documented in the chart, usually in time units of minutes.
Summary. All seven of these components (history, examination, medical decision-making, patient counseling, coordination of care, problem severity, and time spent with the patient) are necessary for appropriate chart documentation to justify billing for pharmacist-physician collaborative DTMSs.
Billing and reimbursement
Billing for pharmacist-physician collaborative DTMS requires the use of the physician's unique provider identification number (UPIN) because the service provided to patients utilizes an incidence-to physician visit billing mechanism. The most common billing form to be completed is the CMS-1500 form, formerly called the HCFA-1500 form. The CMS-1500 form can be accessed at http://cms.hhs.gov/providers/edi/ cms1500.pdf. Additional information about the CMS-1500 form can be accessed at www.cms.hhs.gov/ forms. The billing forms must include patient demographics, the physician's UPIN, the CPT codes for evaluation and management, the International Classification of Disease codes, the laboratory tests ordered, payment types, the patient's signature, and the providers' (pharmacist and physician) signatures. Various types of billing codes (e.g., CPT codes) are assigned for different health care settings (e.g., inpatient, outpatient, new patients, and established patients). Categories of CPT codes correlate with services provided to established patients in the outpatient clinic, including the three major key components and the four contributory components described above. Table 2 summarizes the CPT codes for collaborative DTMSs for established patients in primary care clinics.
To illustrate proper billing for cognitive services rendered by pharmacists, we present a patient case. An established patient of a physician was diagnosed as having type 2 diabetes mellitus (chief complaint), and the physician requested that the pharmacist collaborate with him in managing the patient's drug therapy. The pharmacist and the physician both provided care for the patient during this office visit. A sample SOAP note is provided in Appendix A, and a synopsis of the evaluation and management of the patient is shown in Appendix B.
As shown in Table 2 , the CPT code of 99214 is appropriate for collaborative DTMSs in this case (two of the three major key components are required-comprehensive history, detailed examination, and moderate complexity of medical decisionmaking). Codes 82962 and V65.49 could also be applied. Most of the pharmacist-physician collaborative care at our family medicine clinic is We have found that pharmacistphysician collaborative practice can be a financially successful endeavor. Since our collaborative service was established, we have successfully provided collaborative DTMSs for patients with diabetes, hypertension, thyroid disorder, hyperlipidemia, or asthma; those taking anticoagulants; and those needing assessments to prevent adverse reactions and drug interactions. The CPT codes for which we billed and were successfully reimbursed include 99211, 99212, 99213, 99214 (75% of claims), 99215, and 82962. Our average reimbursement rate, when compared with the amount billed, is approximately 70%.
Discussion and conclusion
As pharmacists strive to receive reimbursement for cognitive services, we should remember that our primary obligation is to help patients improve their health indicators (e.g., a decrease in glycosylated hemoglobin levels). Our motivation to provide cognitive services to our patients should simply be to make such services available to them. Establishing a collaborative DTMS presents many challenges and obstacles, but they should not lead to discouragement. Rather, pharmacists should be diligent and continue to explore ways in which they could provide optimal medication therapy to patients through appropriate channels that also facilitate reimbursement. Ultimately, our obligation is to demonstrate and promote the value of pharmaceutical care services. , and health maintenance follow-up (foot exam, eye exam, dental exam). The estimated 10-year coronary heart disease risk (Adult Treatment Panel III guidelines) in this patient is 16%. Gave patient pamphlets and educational materials on the overview of diabetes, nutrition, exercise, acute complications, chronic complications, goal setting for behavior change strategies, and standards of care information. Recommended flu vaccine and pneumococcal vaccine.
Plan: Therapeutic goals-prevent and slow the progression of DM-associated complications; HbA 1c 6-7%, fasting BG 80-120 mg/dL, postprandial BG 120-140 mg/dL, total cholesterol < 200 mg/dL, LDL cholesterol < 100 mg/dL, HDL cholesterol > 60 mg/dL, TG < 150 mg/dL, BP < 120/80 mm Hg. 
